A Japanese research team led by Dr. Hirokazu Komatsu, a researcher at the International Center for Materials Nanoarchitectonics (MANA: Director: Masakazu Aono) of the National Institute for Materials Science (NIMS; President: Sukekatsu Ushioda) in charge of the YAMATO-MANA Program, and Dr. Katsuhiko Ariga, MANA Principal Investigator and Supermolecule Unit Leader, in collaboration with Project Professor Yutaka Shido and Professor Kotaro Oka of the Department of Biosciences and Informatics, Faculty of Science and Technology, Keio University (President: Atsushi Seike), succeeded for the first time in the world in developing an imaging method for visualization of nicotine-adenine dinucleotide derivative (NAD(P)H) in a cell, a coenzyme broadly related to vital activity and illness, which had previously been elusive.
Fluorescent imaging, which is intended to identify and visualize a substance in a cell by attaching a fluorescent substance to it, is an effective method of exploring vital phenomena. However, this method is incapable of detecting or measuring molecules exceeding a certain level of complexity. Furthermore, when green fluorescent protein (GFP), the famous Nobel Prize winning achievement, is used as a sensor, it is necessary to introduce a special gene into the cell, and therefore this method is not broadly applicable to all cells. In light of this, there was a call for the development of a fluorescent imaging method to visualize NAD(P)H, a substance universally related to a number of vital phenomena and diseases, as a key technology for the advancement of life science, but it has proven elusive due to the low reactivity of NAD(P)H to fluorescent substances.
- The research group succeeded in developing a new fluorescent probe that specifically reacts with NAD(P)H, and achieved fluorescent imaging of NAD(P)H for the first time in the world, through the combined use of the new probe and an artificial promoter capable of promoting reactivity.
- The development of this new NADH imaging method is expected to be applicable to various purposes, e.g. promoting early detection and supporting cancer treatment by detecting leakage of NADH from invasive cancers, diagnosing liver dysfunction by detecting excessive NADH caused by cirrhosis of the liver, and elucidating the lack of NADH in patients with brain or neurological diseases such as Alzheimer's Disease, depression, and Parkinson's Disease. The new method will also be a great advantage in other life sciences research.